Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
08:00am, Monday, 15'th Sep 2025
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”)
Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 03'rd Sep 2025
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update
02:41pm, Friday, 22'nd Aug 2025
I maintain a Strong Buy on Krystal Biotech, as the pause in melanoma trial enrollment is offset by promising progress in inhaled KB707 for NSCLC. Inhaled KB707 achieved a 36% ORR in heavily pretreated
PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB7
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
10:01am, Tuesday, 05'th Aug 2025
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript
12:42pm, Monday, 04'th Aug 2025
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Kathryn A. Romano - Executive VP & Chief Accounting Officer Krish S.
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
09:15am, Monday, 04'th Aug 2025
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $0.86 per share a year ago.
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth
11:06am, Monday, 28'th Jul 2025
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
01:11pm, Thursday, 10'th Jul 2025
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
07:00am, Wednesday, 09'th Jul 2025
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
09:10am, Saturday, 28'th Jun 2025
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
3 Promising Genomics Stocks to Keep an Eye On in 2025
09:06am, Friday, 27'th Jun 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
12:21pm, Wednesday, 25'th Jun 2025
Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.
